Status:

COMPLETED

Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males

Lead Sponsor:

Boehringer Ingelheim

Conditions:

Healthy

Eligibility:

MALE

21-50 years

Phase:

PHASE1

Brief Summary

Study to obtain information about the safety and tolerability of BIIL 248 BS, to find the pharmacologically active dose range for the two formulations PSE 1% and WIF tablets by determination of the su...

Eligibility Criteria

Inclusion

  • Healthy male subjects as determined by results of screening
  • Age ≥ 21 and ≤ 50 years
  • Broca ≥ - 20% and ≤ + 20%
  • Signed written informed consent in accordance with Good Clinical Practice and local legislation

Exclusion

  • Results of the medical examination or laboratory tests that are judged by the clinical investigator to differ significantly from normal clinical values
  • Known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
  • Known history of orthostatic hypotension, fainting spells or blackouts
  • Chronic or relevant acute infections
  • History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  • Intake of a drug with a long half-life (≥ 24 hours) within at least one month or less than ten half-lives of the respective drug before enrolment in the study
  • Intake of any other drugs which might influence the results of the trial during the week previous to the start of the study
  • Participation in another study with an investigational drug within the last two months preceding this study
  • Smokers (\> 5 cigarettes or 2 cigars or 2 pipes/day)
  • Volunteer who is not able to refrain from smoking on study days
  • Alcohol abuse (more than 60 g of alcohol per day)
  • Drug abuse
  • Excessive physical activities (e.g. competitive sports) within the last week before the study
  • Blood donation within the last 4 weeks (≥ 100 ml)

Key Trial Info

Start Date :

June 1 1998

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

95 Patients enrolled

Trial Details

Trial ID

NCT02265302

Start Date

June 1 1998

Last Update

October 15 2014

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.